Peptide Nasal Sprays in 2026: Compounds, Evidence, and Research 

Peptide nasal sprays attract attention because they combine an accessible delivery format with ambitious claims about cognition, sleep, mood, and longevity. Evaluating those claims requires more than identifying the compound inside the bottle. The key questions are whether it has been studied through the nasal route, what investigators measured, and whether the results support the outcome being advertised.

A brain-scan finding does not establish better memory. An injection study does not validate a nasal formulation. Results in cultured cells do not demonstrate longer human life. This guide compares the evidence behind commonly discussed compounds and explains where important research gaps remain.

Quick Summary: What Does Peptide Nasal-Spray Research Show?

Quick Answer: Published human studies exist for compounds including Semax, Selank, oxytocin, and intranasal bremelanotide, but they address different questions. The studies discussed below do not establish a single “best” peptide nasal spray or validate every commercial formulation. The most useful comparison separates exposure measurements, clinical outcomes, and evidence from other routes or experimental models.

Why the Delivery Route Matters

When reviewing a publication, identify the question it was designed to answer. Exposure studies examine whether a substance reaches the blood, cerebrospinal fluid, or another sampled compartment. Clinical studies examine outcomes such as symptoms or function. Evidence of exposure can justify further investigation without establishing a meaningful benefit.

Intranasal oxytocin illustrates this distinction. A small human study reported increases in blood and cerebrospinal-fluid concentrations after administration. That finding addresses delivery; it does not by itself demonstrate improvements in relationships, social confidence, or wellbeing. Read the Striepens et al. study.

For related background, explore our articles on nose-to-brain peptide delivery and how peptide administration routes differ. Evidence should still be assessed against the exact formulation and outcome under discussion.

Semax: Brain-Network Research and Its Limits

Semax appears prominently in cognitive peptide research. A 2018 publication examined its effects on the brain’s default mode network, making it relevant to investigations of brain-network activity. Lebedeva et al., 2018.

The interpretation must remain specific. Brain-network findings are not equivalent to demonstrating reliable improvements in everyday concentration, learning, or productivity. Claims about those outcomes require studies designed to measure them directly.

Safety also needs its own evidence base. The FDA identifies potential immunogenicity concerns involving Semax preparations, including issues associated with aggregation and peptide-related impurities. FDA safety information.

Related reading: Adamax vs Semax: molecular structure and research.

Selank: Human Anxiety Research with Important Boundaries

A randomized comparative study evaluated 62 patients with generalized anxiety disorder and neurasthenia. Investigators reported similar anxiety-reducing effects in the Selank and medazepam groups, alongside additional reported effects in the Selank group. Zozulia et al., 2008.

This is a human research signal, but its scope matters. Findings in patients with particular diagnoses do not establish benefits for healthy people seeking everyday calm or focus. A small comparative study also cannot establish long-term safety or validate all commercially available preparations.

The FDA notes missing safety information and potential immunogenicity concerns for compounded Selank acetate. FDA safety information.

Our Semax and Selank guide provides related background. Evidence for either compound alone should not be treated as proof of a combination’s effectiveness.

Oxytocin: Exposure and Behaviour Are Different Questions

Oxytocin researchers have measured increases in cerebrospinal-fluid and blood concentrations following intranasal administration. The study did not establish that every proposed behavioural effect follows from those changes. Striepens et al., 2013.

A claim about social behaviour needs evidence measuring that behaviour in a defined population under controlled conditions. Concentration measurements are useful, but they answer a different question.

PT-141: Approval Is Specific to a Product and Route

PT-141, also called bremelanotide, has been studied intranasally. A randomized phase I study involving 24 healthy participants assessed exposure, tolerability, and interactions with ethanol. Its findings apply to the preparation and conditions studied; it was not a broad demonstration of long-term nasal-spray effectiveness. Clayton et al., 2017.

The FDA approval for Vyleesi concerns subcutaneous injection. That approval does not establish approval of a nasal product containing the same active molecule. FDA approval letter.

DSIP, Noopept, Epithalon, NAD+ and 5-Amino-1MQ

The nasal-spray category often groups compounds with very different research backgrounds, including substances that are not conventional peptides. The source overview includes all five below; appearing together in a list does not imply comparable evidence.

Epithalon provides a clear example. A frequently cited study reported telomere elongation and additional divisions in cultured human fetal fibroblasts. These laboratory findings do not establish that a nasal spray extends lifespan or reverses ageing in people. Khavinson et al., 2004.

For additional compound background, see our 5-Amino-1MQ and NNMT research guide.

Melanotan II: Safety Signals Deserve Separate Attention

The FDA identifies published reports of serious adverse events associated with Melanotan II, including priapism, neurological complications, and melanoma reports. Case reports do not establish causation in every instance, but they are significant safety signals. A nasal delivery format does not demonstrate that these concerns have been resolved. FDA safety information.

How to Evaluate Peptide Nasal-Spray Claims

• Match the route: Was the compound actually studied intranasally?
• Identify the model: Were the findings obtained in cells, animals, or humans?
• Check the outcome: Did investigators measure exposure, a biomarker, symptoms, or practical function?
• Examine the comparison: Was there an appropriate control group?
• Read the safety results: How many participants were observed, and for how long?
• Match the formulation: Does the evidence apply to the preparation being discussed?

A claim becomes less reliable each time it moves beyond the study that supports it. A useful evidence review makes those limits visible.

Canadian Context: Research Materials and Authorized Medicines

Health Canada’s April 2026 advisory on unauthorized injectable peptides warns that these products have not been assessed for safety, efficacy, and quality. It also states that research-use labelling does not exempt products from regulatory requirements. Although the advisory addresses injectables, this labelling distinction matters when interpreting research-product marketing. Health Canada advisory.

For a Canadian reader evaluating a therapeutic claim, the question is whether the specific drug product is authorized, not simply whether its ingredient appears in a scientific paper.

Related Standard Labs Research Products

For laboratory catalogue reference, Standard Labs lists Semax, Selank, DSIP, Epithalon, NAD+, and 5-Amino-1MQ.

These links identify research materials, not clinically validated nasal sprays. A compound listing does not establish suitability for nasal administration, and research materials should not be treated as ready-to-use medicines.